Epinephrine is under clinical development by ARS Pharmaceuticals and currently in Pre-Registration for Anaphylaxis. According to GlobalData, Pre-Registration drugs for Anaphylaxis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Epinephrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine (ARS-1) is under development for the treatment of anaphylaxis caused by severe allergic reactions to food, medications, insect bites, asthma, urticaria, seasonal allergic rhinitis and infectious rhinitis. It is formulated as spray and administered through intranasal route. The drug candidate acts by targeting ADRA1, ADRA2, ADRB1, ADRB2 and ADRB3 adrenergic receptors. It is developed based on Intravail technology.
ARS Pharmaceuticals overview
ARS Pharmaceuticals, formerly Silverback Therapeutics, focuses on the discovery, development and commercialization of medicines for the treatment of chronic viral infections, cancer, and other serious diseases. The company is advancing SBT6050 for breast cancer, gastric cancer, and non-small cell lung cancer (NSCLC); SBT6290 for bladder cancer, triple-negative breast cancer (TNBC), and head and neck (H&N) cancer; and SBT8230 for chronic hepatitis B virus. ARS Pharmaceuticals is also advancing pre-clinical candidates for the treatment of solid tumors and liver fibrosis. The company employs its proprietary, ImmunoTAC technology platform to advance the development of its pipeline products. ARS Pharmaceuticals is headquartered in Seattle, Washington, the US.
For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.